What is the appropriate management plan for a resident physician with rotating shift work who has chronic insomnia, frequent use of alprazolam (Xanax) for sleep, snoring with dry mouth, possible obstructive sleep apnea, restless‑legs symptoms, bruxism treated with a dental guard, and is currently taking venlafaxine 225 mg daily for anxiety and depression?

Management of Chronic Insomnia in a Shift-Working Resident with Multiple Sleep Comorbidities

This resident requires immediate discontinuation of alprazolam for sleep, referral for cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment, evaluation for obstructive sleep apnea with polysomnography, and treatment of restless legs syndrome—likely exacerbated by venlafaxine—with gabapentin or pregabalin. 1, 2

Immediate Priorities

1. Discontinue Alprazolam (Xanax) for Sleep

• Benzodiazepines are not recommended as first-line therapy for chronic insomnia and carry significant risks including tolerance, dependence, and long-term harms (dementia, falls, death) 1, 3
• The increasing frequency of use ("using it more often") signals developing dependence
• Taper gradually rather than abrupt cessation to avoid withdrawal symptoms (anxiety, insomnia, agitation, sensory disturbances) 4
• Alprazolam is particularly problematic due to its short half-life and high abuse potential

2. Initiate CBT-I as First-Line Treatment

CBT-I is the gold-standard first-line therapy for chronic insomnia, superior to all pharmacologic options in long-term outcomes 1, 2, 3

• CBT-I shows equivalent short-term results (2-4 weeks) to medications but superior long-term efficacy 1
• Fewer adverse effects compared to pharmacotherapy
• Benefits persist after treatment discontinuation, unlike medications
• Can be delivered via internet-based platforms if in-person access is limited 1
• Sleep hygiene education alone is ineffective and potentially harmful if it delays effective treatment 1

3. Evaluate and Treat Obstructive Sleep Apnea (OSA)

Order polysomnography immediately given multiple red flags:

• Snoring
• Dry mouth upon awakening (mouth breathing during sleep)
• Daytime headaches
• Unrefreshing sleep despite adequate sleep opportunity
• Bruxism (associated with OSA)

If OSA is confirmed, CPAP therapy may improve both OSA and RLS symptoms 5—over 70% of patients with comorbid RLS-OSA showed reduced RLS medication needs after CPAP initiation in some cohorts.

4. Address Restless Legs Syndrome (RLS)

The venlafaxine 225 mg daily is likely worsening or causing RLS symptoms 6

RLS treatment algorithm:

• First-line: Gabapentin enacarbil or pregabalin (alpha-2-delta calcium channel ligands) 6
  • Particularly appropriate here given likely venlafaxine-induced/exacerbated RLS
  • Avoid dopamine agonists as first-line due to augmentation risk
• Check ferritin level; supplement if <75 mcg/L
• Do not discontinue venlafaxine abruptly due to severe discontinuation syndrome risk 4
• Consider switching to an antidepressant less likely to worsen RLS (e.g., bupropion, mirtazapine) in consultation with prescribing psychiatrist

5. Manage Shift Work Sleep Disorder

Specific strategies for rotating shifts:

• Strategic caffeine use: limit to early shift hours, none within 6 hours of intended sleep
• Current 3 cups daily may be excessive and contributing to insomnia
• Light exposure management: bright light during work hours, darkness during sleep periods
• Consistent pre-sleep routine despite variable schedule
• Consider strategic napping (20-30 minutes) before night shifts

Pharmacotherapy Considerations (Only if CBT-I Insufficient)

If CBT-I fails or is unavailable, and pharmacotherapy is necessary 1, 2:

Preferred Options:

1. Low-dose doxepin 3-6 mg for sleep maintenance insomnia 1, 2

   • Minimal next-day effects
   • No abuse potential
   • Effective for middle-of-night awakenings

2. Dual orexin receptor antagonists (DORAs): suvorexant, lemborexant, or daridorexant 2, 7

   • Inhibit wakefulness rather than induce sedation
   • No rebound insomnia or withdrawal
   • No abuse potential
   • Daridorexant has ideal 8-hour half-life 7

3. Non-benzodiazepine BZRAs (eszopiclone, zolpidem, zaleplon) 2

   • Short-term use only
   • Lower abuse potential than benzodiazepines but still present
   • Risk of next-day impairment, especially concerning for shift workers

Avoid:

• Trazodone: negative recommendation from AASM 2
• Melatonin: ineffective for chronic insomnia per guidelines 2
• Diphenhydramine: negative recommendation 2
• Continued benzodiazepines: not recommended for chronic insomnia 1, 8

Addressing Venlafaxine-Related Sleep Issues

Venlafaxine commonly causes insomnia, anxiety, and nervousness 4:

• 18% of venlafaxine-treated patients report insomnia vs. 10% on placebo
• 13% report nervousness vs. 6% on placebo
• Venlafaxine can induce or worsen bruxism 9—may be contributing to teeth grinding despite dental guard use

Coordinate with prescribing psychiatrist to consider:

• Dose reduction if clinically appropriate
• Switching to alternative antidepressant with better sleep profile
• Never abruptly discontinue—requires gradual taper to avoid severe discontinuation syndrome 4

Monitoring and Follow-Up

• Reassess in 2-4 weeks after CBT-I initiation
• Polysomnography results and CPAP titration if indicated
• Monitor RLS symptom response to gabapentin/pregabalin
• Track alprazolam taper progress and withdrawal symptoms
• Evaluate need for short-term pharmacotherapy bridge during CBT-I

Critical Pitfalls to Avoid

1. Do not continue benzodiazepines long-term—associated with dementia, falls, and mortality 3, 8
2. Do not use sleep hygiene education as standalone treatment—ineffective and delays appropriate care 1
3. Do not start dopamine agonists for RLS—high augmentation risk; use gabapentinoids first 6
4. Do not ignore OSA evaluation—multiple clinical indicators present and untreated OSA worsens insomnia
5. Do not abruptly stop venlafaxine—severe discontinuation syndrome risk 4
6. Do not overlook shift work as primary contributor—circadian misalignment requires specific interventions beyond standard insomnia treatment